Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial

International Journal of Cardiology

Volumn 202, Issue , 2016, Pages 589-594

  Durheim, Michael T ^a,b   Cyr, Derek D ^a   Lopes, Renato D ^a,b   Thomas, Laine E ^a   Tsuang, Wayne M ^c   Gersh, Bernard J ^d   Held, Claes ^e   Wallentin, Lars ^e   Granger, Christopher B ^a,b   Palmer, Scott M ^a,b   Al Khatib, Sana M ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Mayo Clinic College of Medicine   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticoagulation; Atrial fibrillation; COPD; Mortality; Stroke

Indexed keywords

APIXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EMBOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; COMPLICATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; EMBOLISM; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84960846405     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.09.062     Document Type: Article

References (23)

1. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
2. P.A. Wolf, R.B. D'Agostino, A.J. Belanger, and W.B. Kannel Probability of stroke: a risk profile from the Framingham Study Stroke 22 1991 312 318
3. P. Buch, J. Friberg, H. Scharling, P. Lange, and E. Prescott Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study Eur. Respir. J. 21 2003 1012 1016
4. J. Li, S.K. Agarwal, A. Alonso, S. Blecker, A.M. Chamberlain, S.J. London, L.R. Loehr, A.M. McNeill, C. Poole, E.Z. Soliman, and G. Heiss Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study Circulation 129 2014 971 980
5. J. Miller, L.D. Edwards, A. Agusti, P. Bakke, P.M. Calverley, B. Celli, H.O. Coxson, C. Crim, D.A. Lomas, B.E. Miller, S. Rennard, E.K. Silverman, R. Tal-Singer, J. Vestbo, E. Wouters, J.C. Yates, W. Macnee, and Evaluation of CLtIPSEI Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort Respir. Med. 107 2013 1376 1384
6. H. Mullerova, A. Agusti, S. Erqou, and D.W. Mapel Cardiovascular comorbidity in COPD: systematic literature review Chest 144 2013 1163 1178
7. J.R. Feary, L.C. Rodrigues, C.J. Smith, R.B. Hubbard, and J.E. Gibson Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care Thorax 65 2010 956 962
8. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W. Verheugt, J. Zhu, L. Wallentin, and Committees A., Investigators Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
9. R.D. Lopes, J.H. Alexander, S.M. Al-Khatib, J. Ansell, R. Diaz, J.D. Easton, B.J. Gersh, C.B. Granger, M. Hanna, J. Horowitz, E.M. Hylek, J.J. McMurray, F.W. Verheugt, L. Wallentin, and Investigators A Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am. Heart J. 159 2010 331 339
10. S. Schulman, C. Kearon, Subcommittee on Control of Anticoagulation of the S, and Standardization Committee of the International Society on T, Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J. Thromb. Haemost. 3 2005 692 694
11. B.J. Leavitt, C.S. Ross, B. Spence, S.D. Surgenor, E.M. Olmstead, R.A. Clough, D.C. Charlesworth, R.S. Kramer, G.T. O'Connor, and Northern New England Cardiovascular Disease Study G. Long-term survival of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery Circulation 114 2006 I430 I434
12. J.R. Enriquez, S.V. Parikh, F. Selzer, A.K. Jacobs, O. Marroquin, S. Mulukutla, V. Srinivas, and E.M. Holper Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry Chest 140 2011 604 610
13. E.S.P.G. de Barros, R.M. Califf, J.L. Sun, J.J. McMurray, R. Holman, S. Haffner, L. Thomas, and R.D. Lopes Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial Int. J. Cardiol. 176 2014 1126 1128
14. R.J. Mentz, P.J. Schulte, J.L. Fleg, M. Fiuzat, W.E. Kraus, I.L. Pina, S.J. Keteyian, D.W. Kitzman, D.J. Whellan, S.J. Ellis, and C.M. O'Connor Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Am. Heart J. 165 2013 193 199
15. R.J. Mentz, M. Fiuzat, D.M. Wojdyla, K. Chiswell, M. Gheorghiade, G.C. Fonarow, and C.M. O'Connor Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF Eur. J. Heart Fail. 14 2012 395 403
16. J.D. Maclay, D.A. McAllister, S. Johnston, J. Raftis, C. McGuinnes, A. Deans, D.E. Newby, N.L. Mills, and W. MacNee Increased platelet activation in patients with stable and acute exacerbation of COPD Thorax 66 2011 769 774
17. A. Undas, P. Kaczmarek, K. Sladek, E. Stepien, W. Skucha, M. Rzeszutko, I. Gorkiewicz-Kot, and W. Tracz Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment Thromb. Haemost. 102 2009 1176 1182
18. R.M. Reed, M. Eberlein, R.E. Girgis, S. Hashmi, A. Iacono, S. Jones, G. Netzer, and S. Scharf Coronary artery disease is under-diagnosed and under-treated in advanced lung disease Am. J. Med. 125 2012 (1228 e1213-1228 e1222)
19. R.G. Barr, D.A. Bluemke, F.S. Ahmed, J.J. Carr, P.L. Enright, E.A. Hoffman, R. Jiang, S.M. Kawut, R.A. Kronmal, J.A. Lima, E. Shahar, L.J. Smith, and K.E. Watson Percent emphysema, airflow obstruction, and impaired left ventricular filling N. Engl. J. Med. 362 2010 217 227
20. H. Watz, B. Waschki, T. Meyer, G. Kretschmar, A. Kirsten, M. Claussen, and H. Magnussen Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation Chest 138 2010 32 38
21. J.J. McMurray, J.A. Ezekowitz, B.S. Lewis, B.J. Gersh, S. van Diepen, J. Amerena, J. Bartunek, P. Commerford, B.H. Oh, V.P. Harjola, S.M. Al-Khatib, M. Hanna, J.H. Alexander, R.D. Lopes, D.M. Wojdyla, L. Wallentin, C.B. Granger, A. Committees, and Investigators Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial Circ. Heart Fail. 6 2013 451 460
22. M.C. Bahit, R.D. Lopes, D.M. Wojdyla, S.H. Hohnloser, J.H. Alexander, B.S. Lewis, P.E. Aylward, F.W. Verheugt, M. Keltai, R. Diaz, M. Hanna, C.B. Granger, and L. Wallentin Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial Int. J. Cardiol. 170 2013 215 220
23. S.H. Hohnloser, Z. Hijazi, L. Thomas, J.H. Alexander, J. Amerena, M. Hanna, M. Keltai, F. Lanas, R.D. Lopes, J. Lopez-Sendon, C.B. Granger, and L. Wallentin Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur. Heart J. 33 2012 2821 2830